摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-BOC-3-丁基哌嗪 | 928025-60-9

中文名称
(S)-1-BOC-3-丁基哌嗪
中文别名
(3S)-3-丁基-1-哌嗪甲酸叔丁酯
英文名称
(S)-1-Boc-3-butyl-piperazine
英文别名
tert-butyl (3S)-3-butylpiperazine-1-carboxylate
(S)-1-BOC-3-丁基哌嗪化学式
CAS
928025-60-9
化学式
C13H26N2O2
mdl
——
分子量
242.36
InChiKey
ZNICOTLOPCODTO-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    320.5±17.0 °C(Predicted)
  • 密度:
    0.964

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    17
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    41.6
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • Derivative having ppar agonistic activity
    申请人:Itai Akiko
    公开号:US20090286974A1
    公开(公告)日:2009-11-19
    A compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein Ring Q is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, optionally substituted fused aryl or optionally substituted fused heteroaryl, Y 1 is a bond or —NR 6 — or the like, Ring A is optionally substituted nonaromatic heterocyclediyl, a group of the formula: -Y 2 Z 1 - is a group of the formula: R 7 are each independently hydrogen, optionally substituted lower alkyl or the like, R 8 and R 9 are each independently hydrogen or optionally substituted lower alkyl, n is an integer between 1 and 3, Z 1 is a bond, —O—, —S— or —NR 9 —, Ring B is optionally substituted aromatic carbocyclediyl or optionally substituted aromatic heterocyclediyl, Y 3 is a bond, optionally substituted lower alkylene optionally intervened by —O—, optionally substituted lower alkenylene or the like, and Z 2 is COOR 3 or the like.
    化合物的公式(I):其药物可接受的盐或溶剂,其中环Q是可选择的取代的单环芳基,可选择的取代的单环杂芳基,可选择的融合芳基或可选择的融合杂芳基,Y1是键或-NR6-或类似物,环A是可选择的取代的非芳香杂环二基,公式组:-Y2Z1-是公式组:R7各自独立地是氢,可选择的取代的低烷基或类似物,R8和R9各自独立地是氢或可选择的取代的低烷基,n是1到3之间的整数,Z1是键,-O-,-S-或-NR9-,环B是可选择的取代的芳香碳杂环二基或可选择的取代的芳香杂环二基,Y3是键,可选择的取代的低烷基,可选择地介入-O-,可选择的取代的低烯基或类似物,并且Z2是COOR3或类似物。
  • PDE4 Inhibitor
    申请人:Meiji Seika Pharma Co., Ltd.
    公开号:US20160159783A1
    公开(公告)日:2016-06-09
    Provided is a compound represented by formula (1a) or a pharmacologically acceptable salt thereof. However, R 1 to R 6 in the formula each independently represent an alkyl group or the like.
    提供的化合物由式(1a)或其药学上可接受的盐表示。但是,在公式中,R1到R6各自独立地表示烷基或类似物。
  • 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS
    申请人:Les Laboratoires Servier
    公开号:EP3575294A1
    公开(公告)日:2019-12-04
    The present invention discloses compounds according to formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and the compounds of formula I for use in methods of treatment and for use in methods of prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.
    本发明公开了符合式 I 的化合物: 其中R1、R2、R3a、R3b和Cy如本文所定义。 本发明涉及抑制 ADAMTS 的化合物、其生产方法、包含其的药物组合物,以及用于治疗方法和用于预防和/或治疗炎症条件和/或涉及软骨降解和/或破坏软骨稳态的疾病的方法的式 I 化合物。
  • NOVEL PDE4 INHIBITOR
    申请人:Meiji Seika Pharma Co., Ltd.
    公开号:EP3020718B1
    公开(公告)日:2018-12-26
  • US8097610B2
    申请人:——
    公开号:US8097610B2
    公开(公告)日:2012-01-17
查看更多